BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 26, 2026
Home
»
Newsletters
» BioWorld
BioWorld
July 27, 2007
View Archived Issues
Hydra Lands Potential $195M Deal With Pfizer On Pain Drugs
Hydra Biosciences Inc. licensed rights to its TRPV3 antagonist program to Pfizer Inc. in a deal valued at up to $195 million. (BioWorld Today)
Read More
Exelixis Moving Forward On XL647 After GSK Declines
Read More
ATP Sense Channels Link Spinal Cord Injury, Stroke, Diabetes
Read More
Aspreva Restructures, Plans To Look Beyond CellCept
Read More
Revlimid Sales Drive Celgene's Second-Quarter Revenue Growth
Read More
Other News To Note
Read More
Clinic Roundup
Read More
